As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous ...

Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...

From recognising early signs to caregiving boundaries, experts and carers share practical strategies for supporting people ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

When the brain's typical wiring patterns shift from the norm, it leads to psychotic disorders such as schizophrenia and ...

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 2 Olanzapine LAI is designed ...